Radium-223 dichloride
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-RADIUM-223 |
|---|---|
| Type | Drug |
| Aliases | XofigoРадій-223 дихлорид |
| Status | pending_clinical_signoff |
| Diseases | DIS-PROSTATE |
| Sources | SRC-ESMO-PROSTATE-2024 SRC-NCCN-PROSTATE-2025 |
Drug Facts
| Class | Bone-seeking α-emitter |
|---|---|
| Mechanism | Calcium-mimetic α-emitter that incorporates into hydroxyapatite at sites of high bone turnover (osteoblastic metastases). α-radiation has ~100 µm range — high local tumor cell kill with minimal marrow toxicity vs β-emitters. |
| Typical dosing | 55 kBq/kg IV q4 weeks × 6 cycles. Symptomatic bone-predominant mCRPC without visceral metastases (visceral mets exclude — ALSYMPCA exclusion criterion). |
| Ukraine registered | True |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-04-27 |
Notes
ALSYMPCA: OS benefit + symptomatic skeletal-event reduction in bone-predominant mCRPC. ERA-223 caution: avoid combination with abiraterone (use sequentially). UA-access barrier.
Used By
Regimens
REG-RADIUM223-MCRPC- Radium-223 (mCRPC, bone-metastatic)